Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Revenue Up 5 Percent on String Clinical Dx Sales as R&D Spending Hits Profit

NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said first-quarter revenues increased 5 percent as R&D spending rose 17 percent and profit fell 13 percent.
 
Total receipts for the three months ended March 31 increased to $322.5 million from $308.3 million year over year.
 
Revenue from the company’s Clinical Diagnostics segment increased nearly 11 percent to $177.6 million, while receipts from the Life Science division slipped 2 percent to $141.6 million.
 
According to Bio-Rad, increased Clinical Diagnostics sales came “across all product lines,” with notable growth coming from its blood virus and quality-control products.
 
Meantime, Life Sciences revenue was hurt by decreased testing revenues from bovine spongiform encephalopathy and reduced government-sponsored research.
 
R&D spending rose to $32.8 million from $28.1 million year over year.
 
The company said first-quarter profit fell to $27 million from $31.2   million in the year-ago period.
 
Bio-Rad said it had around $230.3 million in cash, cash equivalents, and $241.4 million in short-term investments as of March 31.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.